Based on our results, it can be hypothesized that the prognostic power of PSMA PET in this clinical setting might predominantly reflect these tumour characteristics rather than identifying a specific feature of PCa biological aggressiveness. The gene discussed is FOLH1; the disease is posterior cortical atrophy.